A synbiotic supplement for inflammation and oxidative stress and lipid abnormalities in hemodialysis patients.

What Was Tested

The paper reports a study of Copper (Supplement), published as a randomized controlled trial.

The present study aimed to investigate the effects of a synbiotic supplement on serum systemic inflammation, oxidative stress markers, and lipid profile in hemodialysis patients.

Why It Was Studied

Among the most important risk factors for cardiovascular disease in hemodialysis patients are high concentrations of serum inflammation markers, lipid profiles, and oxidative stress.

Who Took Part

PubMed indexes the participants as middle-aged adults, both men and women.

Fifty hemodialysis patients were randomly allocated to synbiotic and placebo groups.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.

Some participants received a placebo instead of Copper (Supplement), giving a reference point.

What Was Measured

Topics PubMed links to this paper include Biomarkers, Inflammation, Lipids, Oxidative Stress, Renal Dialysis, Risk Factors and Synbiotics.

The authors tagged it with the keywords Hemodialysis, lipid profiles and serum systemic.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement).

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (Hemodialysis international. International Symposium on Home Hemodialysis), a journal based in Canada.

More context: the Copper (Supplement) compound page, all human trials.